Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease

Hypertension

Volumn 63, Issue 3, 2014, Pages 475-482

  Reboldi, Gianpaolo ^a   Angeli, Fabio ^a   De Simone, Giovanni ^b   Staessen, Jan A ^c,d   Verdecchia, Paolo ^e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e Hospital of Assisi   (Italy)

Author keywords

hypertension; hypertrophy, left ventricular; myocardial infarction; prognosis; randomized controlled trial; stroke

Indexed keywords

HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL INFARCTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; ITALY; MALE; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84894457794     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02089     Document Type: Article

References (33)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
2. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-Analysis. Lancet. 2001;358:1305-1315.
3. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
5. Angeli F, Reboldi G, Verdecchia P. Hypertension and the J-curve phenomenon: Implications for tight blood pressure control. Hypertens Res. 2013;36:109-111.
6. Anderson TW. Re-examination of some of the Framingham blood-pressure data. Lancet. 1978;2:1139-1141.
7. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;1:861-865.
8. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581-584.
9. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Boddddhm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27:1360-1369.
10. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med. 2006;144:884-893.
11. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?. JAMA. 1991;265:489-495.
12. Hansson L, Zanchetti A, Carruthers SG, Dahloddddf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
13. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM. Blood-pressure targets in patients with recent lacunar stroke: The sps3 randomised trial. Lancet. 2013;382:507-515.
14. Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
15. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641-650.
16. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (jatos). Hypertens Res. 2008;31:2115-2127.
17. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56:196-202.
18. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): An open-label randomised trial. Lancet. 2009;374:525-533.
19. Randomized study of traditional versus aggressive systolic blood pressure control (cardio-sis): Rationale, design and characteristics of the study population. J Hum Hypertens. 2008;22:243-251.
20. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I, Battistelli M, Bartoccini C, Porcellati C. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol. 1994;74:714-719.
21. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Porcellati C. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol. 1998;31:383-390.
22. Romhilt DW, Estes EH Jr. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J. 1968;75:752-758.
23. Mancia G, De Backer G, Dominiczak A, et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751-1762.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
25. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022-2031.
26. Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens. 2010;28:1356-1365.
27. Lv J, Neal B, Ehteshami P, Ninomiya T, Woodward M, Rodgers A, Wang H, MacMahon S, Turnbull F, Hillis G, Chalmers J, Perkovic V. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: A systematic review and meta-Analysis. PLoS Med. 2012;9:e1001293.
28. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
29. Ishii M. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (jatos). Hypertens Res. 2008;31:2115-2127.
30. Stewart IM. Optimised blood-pressure. Lancet. 1979;2:34.
31. Kovesdy CP, Bleyer AJ, Molnar MZ, Ma JZ, Sim JJ, Cushman WC, Quarles LD, Kalantar-Zadeh K. Blood pressure and mortality in U.S. veterans with chronic kidney disease: A cohort study. Ann Intern Med. 2013;159:233-242.
32. Sundstroddddm J, Sheikhi R, Ostgren CJ, Svennblad B, Bodegård J, Nilsson PM, Johansson G. Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: Cohort study of 34 009 primary care patients. J Hypertens. 2013;31:1603-1610.
33. Sprint Investigators. Systolic blood pressure intervention trial. 2013. Available at: Https://www.sprinttrial.org/public/dspHome.cfm. Accessed October 8, 2013.